Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state

Blood

Volumn 99, Issue 2, 2002, Pages 443-449

  Buonamici, Silvia ^a   Ottaviani, Emanuela ^a   Testoni, Nicoletta ^a   Montefusco, Vittorio ^a   Visani, Giuseppe ^a   Bonifazi, Francesca ^a   Amabile, Marilina ^a   Terragna, Carolina ^a   Ruggeri, Deborah ^a   Piccaluga, Pier Paolo ^a   Isidori, Alessandro ^a   Malagola, Michele ^a   Baccarani, Michele ^a   Tura, Sante ^a   Martinelli, Giovanni ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW CULTURE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 16; CHROMOSOME INVERSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DECISION MAKING; FEMALE; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; PATIENT SELECTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; QUANTITATIVE DIAGNOSIS; RELAPSE; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TRANSCRIPTION REGULATION;

EID: 0037079730     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.2.443     Document Type: Article

References (34)

1. Recurring chromosome abnormalities in leukemia and lymphoma
2. Chromosome 16 abnormalities associated with myeloid malignancies
3. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia
4. Fusion between transcription factor CBFβ/PEBP2β and a myosin heavy chain in acute myeloid leukemia
5. Inv(16) may be one of the only favorable factors in acute myeloid leukemia: A report on 19 cases with prolonged follow-up
6. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis
7. Identification of yeast artificial chromosomes containing the inversion 16 p-arm breakpoint associated with acute myelomonocytic leukemia
8. Molecular cloning and characterization of PEBp2b: The heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2a
9. Human smooth muscle myosin heavy chain gene mapped to chromosomal region 16q12
10. Smooth muscle myosin heavy chain locus (MYH11) maps to 16p13.3-p13.12 and establishes a new region of conserved synteny between human 16p and mouse 16
11. Detection of fusion transcript generated by the inversion 16 chromosome in acute myelogenous leukemia
12. Defining the "absence" of the CBFβ-MYH11 fusion transcripts in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long term complete remission: A call for definition
13. Detection of specific polymerase chain reaction product by utilizing the 5′→3′ exonuclease activity of Thermus aquaticus DNA polymerase
14. Quantitation of minimal residual disease in Philadelphia chromosome-positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR
15. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15; 17) translocation using real-time RT-PCR
16. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay
17. Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): Role of bone marrow transplantation procedures
18. Longterm disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFβ/MYH11 transcript
19. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission
20. Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBFβ/MYH11 positive acute myeloblastic leukemia
21. RT-PCR monitoring of CBFβ/MYH11 in patients with AML and chromosomal inv(16): Variable behavior of the chimeric mRNA during treatment
22. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease
23. Proposals for the classification of acute leukaemias
24. Autologous peripheral blood stem cells transplantation is acute myeloblastic leukaemia and myelodysplastic syndrome patients: Evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods
25. Nonparametric estimation for incomplete observation
26. Heterogeneity in CBFβ/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16; 16)(pl 3;q22) in acute myelogenous leukemia
27. Detection and quantification of the transcript associated with the inv(16) in presentation and follow-up samples from patients with AML
28. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse
29. Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported highdose cytarabine and mitoxantrone
30. Remission induction therapy for adults with acute myelogenous leukemia: Towards the ICE age?
31. MEC (mitoxantrone, etoposide and intermediate dose cytarabine): An effective induction regimen for previously untreated acute non-lymphocytic leukemia
32. Use of peripheral blood stem cell for autologous transplantation acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells
33. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia
34. FLANG (fludarabine + high-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of "poor risk" acute myeloid leukemias